Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sab Biotherapeutics Inc (SABS)

Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,303
  • Shares Outstanding, K 9,229
  • Annual Sales, $ 2,240 K
  • Annual Income, $ -42,190 K
  • 60-Month Beta 0.68
  • Price/Sales 12.04
  • Price/Cash Flow N/A
  • Price/Book 0.51
Trade SABS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.13
  • Number of Estimates 2
  • High Estimate -1.02
  • Low Estimate -1.24
  • Prior Year -1.40
  • Growth Rate Est. (year over year) +19.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.70 +5.19%
on 06/24/24
3.25 -12.61%
on 07/11/24
+0.26 (+10.08%)
since 06/18/24
3-Month
2.36 +20.34%
on 05/23/24
4.65 -38.92%
on 04/22/24
-1.45 (-33.80%)
since 04/19/24
52-Week
2.36 +20.34%
on 05/23/24
10.50 -72.95%
on 10/30/23
-5.76 (-66.98%)
since 07/19/23

Most Recent Stories

More News
Promising Upsides on these Biotech Penny Stocks

These three biotech stocks each have a consensus Buy rating. While they are down from historic highs, impressive upsides make them worth consideration.

VTVT : 20.40 (-7.27%)
SABS : 2.84 (-0.35%)
GMDA : 0.0327 (-18.25%)
ICR Hosts SAB Biotherapeutics CEO Eddie Sullivan on the Welcome to the Arena Podcast

ICR , a leading strategic communications and advisory firm, is pleased to announce that Eddie Sullivan, PhD, co-founder, President and CEO of SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical...

SABS : 2.84 (-0.35%)
SAB Biotherapeutics Provides Company Update for Q2 2022 Financial Results

Expects cash is sufficient to fund operations for the forward twelve months...

SABS : 2.84 (-0.35%)
SABSW : 0.0500 (+30.55%)
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down

SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

SABS : 2.84 (-0.35%)
SABSW : 0.0500 (+30.55%)
SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer

SIOUX FALLS, S.D., June 06, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

SABS : 2.84 (-0.35%)
SABSW : 0.0500 (+30.55%)
SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering Summit

In-person presentation titled ‘Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutics’ to take place on June 7 in Park City,...

SABS : 2.84 (-0.35%)
SABSW : 0.0500 (+30.55%)
SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results

Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel...

SABS : 2.84 (-0.35%)
SABSW : 0.0500 (+30.55%)
SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference

SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), announced today its participation at the H.C. Wainwright Global...

SABSW : 0.0500 (+30.55%)
SABS : 2.84 (-0.35%)
SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors

SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel...

SABS : 2.84 (-0.35%)
SABSW : 0.0500 (+30.55%)
SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results

SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised...

SABS : 2.84 (-0.35%)
SABSW : 0.0500 (+30.55%)

Business Summary

SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress...

See More

Key Turning Points

3rd Resistance Point 3.31
2nd Resistance Point 3.19
1st Resistance Point 3.01
Last Price 2.84
1st Support Level 2.72
2nd Support Level 2.60
3rd Support Level 2.43

See More

52-Week High 10.50
Fibonacci 61.8% 7.39
Fibonacci 50% 6.43
Fibonacci 38.2% 5.47
Last Price 2.84
52-Week Low 2.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar